ZimVie (ZIMV, Financial) has introduced its Immediate Molar Implant System to the United States market, marking a significant enhancement to its existing TSX and T3 PRO Implant lines. This new solution aims to address the complexities associated with molar implants, offering dental providers a streamlined approach to treatments.
The Immediate Molar Implant System is designed to reduce treatment time for patients, providing a quicker and more cost-effective solution for those in need of molar tooth restoration. This development reflects ZimVie's dedication to advancing dental technology and improving patient outcomes with more predictable and long-lasting results.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for ZimVie Inc (ZIMV, Financial) is $17.28 with a high estimate of $22.12 and a low estimate of $15.00. The average target implies an upside of 84.03% from the current price of $9.39. More detailed estimate data can be found on the ZimVie Inc (ZIMV) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, ZimVie Inc's (ZIMV, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ZimVie Inc (ZIMV, Financial) in one year is $15.38, suggesting a upside of 63.79% from the current price of $9.39. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ZimVie Inc (ZIMV) Summary page.
